MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.vaccine.2026.128304

Медицинская библиотека · Vaccine · 2026

A novel SARS-CoV-2 mRNA virus-like particle vaccine is highly potent and well tolerated in adults in a phase 1 randomized clinical trial.

Oyedele Temitope, Park Rachel, Morales Kelly, Jain Manish, Sher Lawrence, Vutikullird Apinya, Isaacs Abby, Jepson Brett, Shoemaker Kathryn, Stanley Ann Marie, Lee Joseph, Handelsman Cindy, Berman Stacey Cromer, Chang Lee-Jah

СтатьяРандомизированное исследованиеКлиническое исследование I фазыПеревод пока не подготовлен

Аннотация

BACKGROUND

The need for SARS-CoV-2 vaccines with improved potency, lower reactogenicity, broader coverage, and prolonged protection persists. We examined the safety and immunogenicity of two ferritin scaffold-based self-assembling SARS-CoV-2 mRNA virus-like particle (VLP) vaccines.

METHODS

In this, randomized, Phase I, open-label, active-controlled study (www.

CLINICALTRIALS: govNCT06147063) participants received a single 5 μg or 10 μg intramuscular injection of AZD9838 (BA.4/5 variant) or AZD6563 (XBB.1.5 variant), or 30 μg BNT162b2, a licensed mRNA vaccine (XBB.1.5 variant). The primary safety endpoint was the incidence of solicited adverse reactions (ARs) through Day 8, unsolicited adverse events (AEs) through Day 29, and serious AEs (SAEs), medically attended AEs (MAAEs), and AEs of special interest (AESIs) through Day 361. The primary immunogenicity endpoint was to characterize the neutralizing antibody (nAb) responses to the ancestral and Omicron (BA.4/5, XBB.1.5) variants at Day 29; characterization of nAb response to Omicron JN.1 was an exploratory analysis.

RESULTS

In total, 166 participants aged 18-64 years and 76 participants ≥65 years of age were vaccinated. AZD9838 and AZD6563 were well-tolerated at both dosages. Overall, fewer solicited ARs were reported with AZD9838 and AZD6563 versus BNT162b2. Unsolicited AEs were similar between groups; no related SAEs, AESIs, or MAAEs were reported to Day 180. Day 29 nAb GMTs were higher following 10 μg AZD6563 versus 5 μg and higher than AZD9838 across variants and age groups, remaining above baseline and similar to BNT162b2 at Day 180; 10 μg AZD6563 resulted in nAb GMTs similar to BNT162b2 in both age groups.

CONCLUSION

By combining mRNA vaccine technology with VLP-based antigen display, we developed two candidate SARS-CoV-2 vaccines, AZD9838 and AZD6563, that were well tolerated versus a licensed mRNA vaccine, BNT162b2. Furthermore, the variant-matched AZD6563 generated a similar immunogenicity to BNT162b2 but at one third of the dosage (10 μg versus 30 μg).

Для цитирования: Oyedele Temitope, Park Rachel, Morales Kelly, Jain Manish, Sher Lawrence, Vutikullird Apinya, Isaacs Abby, Jepson Brett, Shoemaker Kathryn, Stanley Ann Marie, Lee Joseph, Handelsman Cindy, Berman Stacey Cromer, Chang Lee-Jah. A novel SARS-CoV-2 mRNA virus-like particle vaccine is highly potent and well tolerated in adults in a phase 1 randomized clinical trial.. Vaccine. 2026. DOI: 10.1016/j.vaccine.2026.128304.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.